ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
82.295
0.02%
Bitcoin
67,725.69
-0.63%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) News

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BMY
DateTimeSourceHeadlineSymbolCompany
07/19/20246:59AMBusiness WireBristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular CarcinomaNYSE:BMYBristol Myers Squibb Co
07/08/20246:59AMBusiness WireBristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation DayNYSE:BMYBristol Myers Squibb Co
06/21/20247:30PMBusiness WireBristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)NYSE:BMYBristol Myers Squibb Co
06/21/20246:59AMBusiness WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous NivolumabNYSE:BMYBristol Myers Squibb Co
06/20/20246:59AMBusiness WireBristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024NYSE:BMYBristol Myers Squibb Co
06/18/20244:16PMBusiness WireBristol Myers Squibb Elects Michael R. McMullen to Board of DirectorsNYSE:BMYBristol Myers Squibb Co
06/18/20246:59AMBusiness WireBristol Myers Squibb Announces DividendNYSE:BMYBristol Myers Squibb Co
06/13/20244:46PMBusiness WireU.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid TumorsNYSE:BMYBristol Myers Squibb Co
06/04/20248:00AMBusiness WireBristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW TrialNYSE:BMYBristol Myers Squibb Co
06/04/20246:59AMBusiness WireBristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:BMYBristol Myers Squibb Co
06/03/202410:13AMBusiness WireBristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual MeetingNYSE:BMYBristol Myers Squibb Co
06/03/20248:00AMBusiness WireBristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
06/01/20248:00AMBusiness WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
05/30/202411:51AMBusiness WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell LymphomaNYSE:BMYBristol Myers Squibb Co
05/29/20246:59AMBusiness WireBristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial CarcinomaNYSE:BMYBristol Myers Squibb Co
05/23/20245:05PMBusiness WireBristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research PlatformsNYSE:BMYBristol Myers Squibb Co
05/23/20247:40AMIH Market NewsOpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More NewsNYSE:BMYBristol Myers Squibb Co
05/23/20246:59AMBusiness WireBristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual MeetingNYSE:BMYBristol Myers Squibb Co
05/22/20246:59AMBusiness WireBristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income CountriesNYSE:BMYBristol Myers Squibb Co
05/22/20243:30AMPR Newswire (US)NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers SquibbNYSE:BMYBristol Myers Squibb Co
05/22/20243:30AMPR Newswire (US)NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers SquibbNYSE:BMYBristol Myers Squibb Co
05/21/20248:45AMBusiness WireBristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible CampaignNYSE:BMYBristol Myers Squibb Co
05/21/20246:59AMBusiness WireBristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
05/16/202410:26AMBusiness WireNew Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque PsoriasisNYSE:BMYBristol Myers Squibb Co
05/15/20248:57PMBusiness WireBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular LymphomaNYSE:BMYBristol Myers Squibb Co
05/13/20247:16AMIH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNYSE:BMYBristol Myers Squibb Co
05/10/20244:30PMBusiness WireBristol Myers Squibb Provides Update on Phase 3 CheckMate -73L TrialNYSE:BMYBristol Myers Squibb Co
05/07/20246:59AMBusiness WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
05/06/20246:59AMBusiness WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...NYSE:BMYBristol Myers Squibb Co
05/06/20246:59AMBusiness WireU.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)NYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Your Recent History

AMEX
PFFV
Global X Variable Rate P...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved